ArticlePharmacoEconomics - open2026

Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2- Early Breast Cancer (EBC): A Canadian Payer Perspective.

Dina Soliman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.